HEALTH TECHNOLOGY APPRAISAL on Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer Assessment Report

To: NICE
FROM: NHS Quality Improvement Scotland

Both these drugs have been reviewed by the Scottish Medicines Consortium and the conclusions seem very similar. I am unaware of any additional data that has been overlooked and feel this is a fair appraisal i.e. bevacizumab has proven activity, but does not meet the current acceptable cost-effectiveness threshold and that for cetuximab the available trial data do not allow a direct assessment of cost-effectiveness (on the basis of survival or quality of life) to be made.

Dr Duncan Jodrell
28 March 2006